About Canopy Biosciences
Canopy Biosciences is a company based in St. Louis (United States) founded in 2016 was acquired by Bruker in September 2020. Canopy Biosciences has raised $4.48 million across 4 funding rounds from investors including Bruker, Ampersand Capital Partners and Kingdom Capital. Canopy Biosciences has completed 2 acquisitions, including Core Diagnostics and ZELLKRAFTWERK. Canopy Biosciences offers products and services including CellScape Instrument, Assay Kits, and CRO Services. Canopy Biosciences operates in a competitive market with competitors including Charles River Laboratories, LabCorp, Cytel, Precision Medicine Group and Veeda Clinical Research, among others.
- Headquarter St. Louis, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.48 M (USD)
in 4 rounds
-
Latest Funding Round
Not available
-
Investors
Bruker
& 7 more
-
Employee Count
Not available
-
Investments & Acquisitions
Core Diagnostics
& 1 more
-
Acquired by
Bruker
(Sep 11, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Canopy Biosciences
Canopy Biosciences offers a comprehensive portfolio of products and services, including CellScape Instrument, Assay Kits, and CRO Services.
Enables high-plex biomarker imaging and spatial quantification for research.
Supports spatial biology experiments with essential consumables and kits.
Offers end-to-end single-cell and RNA sequencing solutions for analysis.
People of Canopy Biosciences
Unlock access to complete
Funding Insights of Canopy Biosciences
Canopy Biosciences has successfully raised a total of $4.48M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Canopy Biosciences
Canopy Biosciences has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Bruker, Ampersand Capital Partners and Kingdom Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Ampersand Capital Partners is focused on investments in healthcare and life sciences.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Tech companies focused VC firm operating across Missouri
|
Locked | Locked | Locked |
Investor details for Canopy Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Canopy Biosciences
Canopy Biosciences has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Core Diagnostics and ZELLKRAFTWERK.
Investment portfolio details for Canopy Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Biomarker analysis and translational support services are provided in diagnostics.
|
Locked | Locked | 2014 | Locked | |
|
Developer of chip cytometry technology
|
Locked | Locked | 2012 | Locked |
Complete acquisition details for Canopy Biosciences
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Canopy Biosciences
Detailed financials for Canopy Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Canopy Biosciences Comparisons
Peer comparison for Canopy Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Canopy Biosciences
Canopy Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Charles River Laboratories, LabCorp, Cytel, Precision Medicine Group and Veeda Clinical Research, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of drug discovery and preclinical development services
|
|
| Locked | Locked | Locked |
Provider of laboratory tests for physicians
|
|
| Locked | Locked | Locked |
Data analysis and statistical solutions are provided for life sciences.
|
|
| Locked | Locked | Locked |
Provider of clinical research, development, and commercialization services for life sciences
|
|
| Locked | Locked | Locked |
Drug development services encompassing clinical trials, bioanalytical support, and real-world evidence in healthcare.
|
|
| Locked | Locked | Locked |
Company offering specialised R&D and clinical development services for the development of precision medicine based drugs and devices
|
Detailed competitors of Canopy Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Canopy Biosciences
Complete news archive for Canopy Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Canopy Biosciences
Canopy Biosciences was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Canopy Biosciences is headquartered in St. Louis, United States. It is registered at St. Louis, Missouri, United States.
Canopy Biosciences is a funded company, having raised a total of $4.48M across 4 funding rounds to date.
Canopy Biosciences provides cell line engineering service based on the CRISPR-Cas9 system. They offer the following services tune gene expression from 100 to complete knockout, model ranges of gene expression reflecting diversity in patient populations, control endogenous gene expressioneliminate artifacts from ectopic expression, and knockdown essential genes where knockout would result in lethality.
Canopy Biosciences's top competitors include LabCorp, Charles River Laboratories and Cytel.
Canopy Biosciences offers CellScape Instrument, Assay Kits, and CRO Services.
Canopy Biosciences has made 2 acquisitions, including Core Diagnostics, and ZELLKRAFTWERK.
Canopy Biosciences has 8 investors. Key investors include Bruker, Ampersand Capital Partners, Kingdom Capital, Missouri Technology, and Pinpoint Holdings.